Phase 1b Study of NXP900 with Osimertinib for Adults with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the combination of NXP900 and osimertinib in adults with advanced, progressing non-small cell lung cancer NSCLC that has mutations in the EGFR gene. This Phase 1b, open-label study aims to explore the safety and treatment effects of this combination in patients who have already been treated with osimertinib. Participants receive escalating doses of NXP900, a drug taken by mouth that inhibits SRC family kinases, together with osimertinib, an oral EGFR inhibitor. This combination is given during the dose exploration phase to find appropriate levels and monitor effects. The study is conducted at multiple centers and involves sequential treatment steps. During the study, participants will be monitored for treatment-related side effects and laboratory changes for up to 30 days after treatment. Researchers will also measure how well the cancer responds to treatment over about 12 months, including the response rate, duration of response, and disease control rate. The study lasts until the completion date in June 2027, with ongoing assessments throughout the treatment period.

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer